344 related articles for article (PubMed ID: 30347494)
21. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
[TBL] [Abstract][Full Text] [Related]
22. A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.
Han X; Knauss EA; Fuente M; Li W; Conlon RA; LePage DF; Jiang W; Renna SA; McKenzie SE; Nieman MT
J Thromb Haemost; 2024 Jun; 22(6):1715-1726. PubMed ID: 38508397
[TBL] [Abstract][Full Text] [Related]
23. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets.
Chen WF; Lee JJ; Chang CC; Lin KH; Wang SH; Sheu JR
Haematologica; 2013 May; 98(5):793-801. PubMed ID: 23065519
[TBL] [Abstract][Full Text] [Related]
24. Protease-activated receptor-induced Akt activation--regulation and possible function.
Reséndiz JC; Kroll MH; Lassila R
J Thromb Haemost; 2007 Dec; 5(12):2484-93. PubMed ID: 17883592
[TBL] [Abstract][Full Text] [Related]
25. Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of β-arrestin.
Smith TH; Li JG; Dores MR; Trejo J
J Biol Chem; 2017 Aug; 292(33):13867-13878. PubMed ID: 28652403
[TBL] [Abstract][Full Text] [Related]
26. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
27. Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.
Van Doren L; Nguyen N; Garzia C; Fletcher EK; Stevenson R; Jaramillo D; Kuliopulos A; Covic L
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e33-e45. PubMed ID: 33267659
[TBL] [Abstract][Full Text] [Related]
28. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
29. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
30. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
31. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.
Arachiche A; de la Fuente M; Nieman MT
PLoS One; 2013; 8(2):e55740. PubMed ID: 23405206
[TBL] [Abstract][Full Text] [Related]
32. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.
Arachiche A; Mumaw MM; de la Fuente M; Nieman MT
J Biol Chem; 2013 Nov; 288(45):32553-32562. PubMed ID: 24097976
[TBL] [Abstract][Full Text] [Related]
33. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
Tricoci P; Neely M; Whitley MJ; Edelstein LC; Simon LM; Shaw C; Fortina P; Moliterno DJ; Armstrong PW; Aylward P; White H; Van de Werf F; Jennings LK; Wallentin L; Held C; Harrington RA; Mahaffey KW; Bray PF
Blood Cells Mol Dis; 2018 Sep; 72():37-43. PubMed ID: 30055940
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
Tourdot BE; Conaway S; Niisuke K; Edelstein LC; Bray PF; Holinstat M
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2644-50. PubMed ID: 25278289
[TBL] [Abstract][Full Text] [Related]
35. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
36. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
Diabet Med; 2022 Aug; 39(8):e14868. PubMed ID: 35514270
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the
Ningtyas D; Thomson RJ; Tarlac V; Nagaraj SH; Hoy W; Mathews JD; Foote SJ; Gardiner EE; Hamilton JR; McMorran BJ
Front Genet; 2020; 11():432. PubMed ID: 32425989
[TBL] [Abstract][Full Text] [Related]
38. Platelet inhibition by P2Y
Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
[TBL] [Abstract][Full Text] [Related]
39. A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.
Rodriguez BAT; Bhan A; Beswick A; Elwood PC; Niiranen TJ; Salomaa V; ; Trégouët DA; Morange PE; Civelek M; Ben-Shlomo Y; Schlaeger T; Chen MH; Johnson AD
Am J Hum Genet; 2020 Aug; 107(2):211-221. PubMed ID: 32649856
[TBL] [Abstract][Full Text] [Related]
40. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
Shankar H; Garcia A; Prabhakar J; Kim S; Kunapuli SP
J Thromb Haemost; 2006 Mar; 4(3):638-47. PubMed ID: 16460446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
